BioCryst Pharmaceuticals
BCRX
BCRX
236 hedge funds and large institutions have $1.23B invested in BioCryst Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 99 increasing their positions, 57 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
14% less capital invested
Capital invested by funds: $1.42B → $1.23B (-$196M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Holders
236
Holding in Top 10
6
Calls
$18.3M
Puts
$4.82M
Top Buyers
| 1 | +$27.8M | |
| 2 | +$13.2M | |
| 3 | +$13M | |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$11.5M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$10M |
Top Sellers
| 1 | -$23.7M | |
| 2 | -$18M | |
| 3 | -$15.9M | |
| 4 |
EP
Eversept Partners
New York
|
-$15.1M |
| 5 |
DM
Deerfield Management
New York
|
-$10.2M |